Therapeutic efficacy of baclofen in refractory gastroesophageal reflux-induced chronic cough

Table 1 Demographic characteristics of 16 patients with refractory gastroesophageal reflux-induced cough

Variables	Value
Sex (male/female)	9/7
Age (yr)	47.8 ± 11.6
Cough duration (mo)	36.0 (27.7)
FEV1 (% predictive value)	93.3 ± 8.3
FVC (% predictive value)	98.1 ± 11.1
FEV1/FVC (%)	80.3 ± 6.1
Cough symptom score
Daytime	3 (0)
Nighttime	1 (1)
DeMeester score	33.1 ± 10.7
SAP (%)
SAP for acid reflux	73.1 (28.2)
SAP for non-acid reflux	71.2 (37.6)

Data on cough duration, cough symptom score and SAP are presented as median (25%-75% interquartile) or mean ± SD. FEV1: Forced expiratory volume in one second; FVC: Forced vital capacity; SAP: Symptom association probability.

Table 2 Comparison of variables in multi-channel intraluminal impedance combined with pH monitoring between patients responsive and unresponsive to baclofen

Variables	Responsive (n = 9)	Unresponsive (n = 7)
DeMeester score	17.9 ± 5.1	45.0 ± 18.0
SAP (%)
SAP for acid reflux	70.0 (28.2)	75.3 (56.0)
SAP for non-acid reflux	87.9 (35.0)	61.6 (59.1)
Acid reflux (n)	26.0 (31.1)	65.0 (51.0)a
Weakly acidic reflux (n)	22.8 (28.7)	22.0 (28.0)
Weakly alkaline reflux (n)	4.0 (22.0)	2.3 (21.7)
Gas reflux (n)	12.0 (51.0)	13.9 (10.0)
Liquid reflux (n)	26.0 (11.0)	24.0 (18.6)
Mixed reflux (n)	45.0 (43.0)	30.4 (33.7)
Proximal extent (n)	13.8 (12.6)	10.5 (11.5)
Bolus exposure (%)	1.1 (1.6)	1.3 (1.2)
Bolus clearance (s)	9.3 (9.1)	8.9 (6.2)

Except for the DeMeester score, the data are presented as median (25%-75% interquartile).

^aP < 0.05 vs responsive patients. SAP: Symptom association probability.

Table 3 Adverse effects in 16 patients during treatment with baclofen n (%)

Adverse effects	Frequency
Somnolence	5 (31.25)
Dizziness	2 (12.50)
Fatigue	3 (18.75)
Nausea	1 (6.25)
Diarrhea	1 (6.25)